Health Cor Management, L.P. Madrigal Pharmaceuticals, Inc. Transaction History

Health Cor Management, L.P.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$108.54 - $125.2 $98 Million - $113 Million	-902,601 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$110.06 - $133.7 $25 Million - $30.4 Million	-227,347 Reduced 20.12%	902,601 $100 Million
Q3 2020 Nov 16, 2020	SELL	$99.78 - $124.21 $6.78 Million - $8.44 Million	-67,936 Reduced 5.67%	1,129,948 $134 Million
Q2 2020 Aug 14, 2020	SELL	$60.13 - $125.71 $12.3 Million - $25.7 Million	-204,366 Reduced 14.57%	1,197,884 $136 Million
Q1 2020 May 15, 2020	BUY	$66.76 - $93.49 $21 Million - $29.4 Million	313,940 Added 28.85%	1,402,250 $93.6 Million
Q4 2019 Feb 14, 2020	BUY	$84.28 - $118.5 $4.81 Million - $6.77 Million	57,090 Added 5.54%	1,088,310 $99.2 Million
Q3 2019 Nov 14, 2019	SELL	$84.4 - $106.53 $88,620 - $111,856	-1,050 Reduced 0.1%	1,031,220 $88.9 Million
Q2 2019 Aug 14, 2019	BUY	$91.13 - $142.5 $12.8 Million - $20 Million	140,280 Added 15.73%	1,032,270 $108 Million
Q1 2019 May 15, 2019	BUY	$103.48 - $143.84 $21 Million - $29.2 Million	203,100 Added 29.48%	891,990 $112 Million
Q4 2018 Feb 14, 2019	BUY	$94.77 - $215.54 $46.6 Million - $106 Million	491,609 Added 249.19%	688,890 $77.7 Million
Q4 2018 Feb 14, 2019	SELL	$94.77 - $215.54 $6.21 Million - $14.1 Million	-65,579 Reduced 24.95%	197,281 $55.2 Million
Q3 2018 Nov 15, 2018	BUY	$207.3 - $300.31 $13.6 Million - $19.7 Million	65,579 Added 33.24%	262,860 $56.3 Million
Q2 2018 Aug 14, 2018	BUY	$101.55 - $313.9 $20 Million - $61.9 Million	197,281 New	197,281 $55.2 Million

335

22.2M

960K

940K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.61B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Health Cor Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Health Cor Management, L.P. with notifications on news.